Mereo Historical Balance Sheet

MREO Stock

USD 4.53 0.09 1.95%

Trend analysis of Mereo BioPharma Group balance sheet accounts such as Other Current Liab of 28.5 K provides information on Mereo BioPharma's total assets, liabilities, and equity, which is the actual value of Mereo BioPharma Group to its prevalent stockholders. By breaking down trends over time using Mereo BioPharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Mereo BioPharma Group latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mereo BioPharma Group is a good buy for the upcoming year.

Mereo BioPharma Inventory

1.31 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

About Mereo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Mereo BioPharma Group at a specified time, usually calculated after every quarter, six months, or one year. Mereo BioPharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Mereo BioPharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Mereo currently owns. An asset can also be divided into two categories, current and non-current.

Mereo BioPharma Balance Sheet Chart

At this time, Mereo BioPharma's Common Stock Total Equity is very stable compared to the past year. As of the 21st of October 2024, Common Stock Shares Outstanding is likely to grow to about 692.4 M, while Short and Long Term Debt Total is likely to drop about 5.7 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Mereo BioPharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Mereo BioPharma Group books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Mereo BioPharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mereo BioPharma Group are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Mereo BioPharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Mereo BioPharma Group current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	16.8M	12.8M	6.0M	5.7M
Total Assets	126.4M	88.1M	66.5M	70.1M

Short Long Term Debt Total Total Assets

Mereo BioPharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		-0.31	-0.29	-0.38	0.85	-0.37	0.24	-0.17	-0.7	0.56	-0.33	0.81	0.19	0.85	-0.47	-0.49	-0.38	-0.63	-0.14	-0.46	-0.45	-0.15	0.83	0.25	-0.44	-0.19
Short Long Term Debt Total	-0.31		0.38	0.79	-0.65	0.33	-0.23	0.68	0.86	-0.29	0.75	-0.73	0.66	-0.69	0.8	0.21	0.56	0.68	0.03	-0.06	0.8	0.68	-0.67	0.56	0.04	0.68
Other Current Liab	-0.29	0.38		0.44	-0.41	0.27	-0.05	-0.12	0.41	-0.26	0.11	-0.38	0.2	-0.33	0.17	0.26	0.28	0.45	0.08	-0.1	0.43	-0.07	-0.38	0.26	0.1	-0.13
Total Current Liabilities	-0.38	0.79	0.44		-0.55	0.01	0.05	0.77	0.71	-0.54	0.67	-0.63	0.36	-0.64	0.63	0.45	0.16	0.69	0.02	0.3	0.53	0.81	-0.58	0.21	0.39	0.77
Total Stockholder Equity	0.85	-0.65	-0.41	-0.55		-0.69	0.37	-0.36	-0.85	0.64	-0.43	0.87	-0.12	0.89	-0.58	-0.59	-0.75	-0.77	-0.08	-0.33	-0.85	-0.35	0.87	-0.05	-0.41	-0.37
Other Liab	-0.37	0.33	0.27	0.01	-0.69		-0.58	0.02	0.42	-0.32	0.04	-0.42	0.2	-0.4	0.12	0.37	0.95	0.32	0.0	-0.06	0.82	0.0	-0.46	0.21	0.09	0.02
Net Tangible Assets	0.24	-0.23	-0.05	0.05	0.37	-0.58		-0.11	-0.4	-0.27	-0.42	0.43	-0.5	0.38	-0.1	0.3	-0.51	0.24	0.29	0.47	-0.43	-0.02	0.5	-0.52	0.47	-0.1
Property Plant And Equipment Net	-0.17	0.68	-0.12	0.77	-0.36	0.02	-0.11		0.59	-0.28	0.76	-0.51	0.51	-0.52	0.67	0.21	0.15	0.41	0.11	0.15	0.43	0.99	-0.46	0.32	0.16	1.0
Net Debt	-0.7	0.86	0.41	0.71	-0.85	0.42	-0.4	0.59		-0.31	0.8	-0.98	0.52	-0.95	0.86	0.22	0.56	0.7	0.2	0.0	0.77	0.55	-0.95	0.43	0.06	0.58
Retained Earnings	0.56	-0.29	-0.26	-0.54	0.64	-0.32	-0.27	-0.28	-0.31		0.1	0.31	0.43	0.38	-0.14	-0.99	-0.35	-0.77	0.1	-0.86	-0.48	-0.36	0.28	0.55	-0.95	-0.31
Accounts Payable	-0.33	0.75	0.11	0.67	-0.43	0.04	-0.42	0.76	0.8	0.1		-0.76	0.75	-0.72	0.78	-0.2	0.18	0.29	0.2	-0.28	0.43	0.7	-0.74	0.64	-0.28	0.75
Cash	0.81	-0.73	-0.38	-0.63	0.87	-0.42	0.43	-0.51	-0.98	0.31	-0.76		-0.4	0.99	-0.82	-0.22	-0.52	-0.66	-0.25	-0.05	-0.69	-0.46	0.99	-0.32	-0.08	-0.51
Non Current Assets Total	0.19	0.66	0.2	0.36	-0.12	0.2	-0.5	0.51	0.52	0.43	0.75	-0.4		-0.31	0.53	-0.46	0.31	0.01	0.17	-0.73	0.44	0.46	-0.4	0.98	-0.65	0.49
Cash And Short Term Investments	0.85	-0.69	-0.33	-0.64	0.89	-0.4	0.38	-0.52	-0.95	0.38	-0.72	0.99	-0.31		-0.8	-0.3	-0.49	-0.66	-0.24	-0.16	-0.66	-0.48	0.98	-0.21	-0.18	-0.52
Net Receivables	-0.47	0.8	0.17	0.63	-0.58	0.12	-0.1	0.67	0.86	-0.14	0.78	-0.82	0.53	-0.8		0.06	0.32	0.64	0.4	-0.02	0.53	0.63	-0.75	0.42	-0.02	0.67
Common Stock Total Equity	-0.49	0.21	0.26	0.45	-0.59	0.37	0.3	0.21	0.22	-0.99	-0.2	-0.22	-0.46	-0.3	0.06		0.37	0.72	-0.07	0.84	0.47	0.29	-0.2	-0.57	0.95	0.23
Non Current Liabilities Total	-0.38	0.56	0.28	0.16	-0.75	0.95	-0.51	0.15	0.56	-0.35	0.18	-0.52	0.31	-0.49	0.32	0.37		0.48	-0.01	-0.05	0.92	0.13	-0.53	0.31	0.09	0.14
Capital Surpluse	-0.63	0.68	0.45	0.69	-0.77	0.32	0.24	0.41	0.7	-0.77	0.29	-0.66	0.01	-0.66	0.64	0.72	0.48		0.27	0.5	0.68	0.46	-0.59	-0.09	0.62	0.42
Other Current Assets	-0.14	0.03	0.08	0.02	-0.08	0.0	0.29	0.11	0.2	0.1	0.2	-0.25	0.17	-0.24	0.4	-0.07	-0.01	0.27		-0.18	0.01	0.1	-0.23	0.16	-0.12	0.11
Other Stockholder Equity	-0.46	-0.06	-0.1	0.3	-0.33	-0.06	0.47	0.15	0.0	-0.86	-0.28	-0.05	-0.73	-0.16	-0.02	0.84	-0.05	0.5	-0.18		0.03	0.21	-0.02	-0.85	0.96	0.18
Total Liab	-0.45	0.8	0.43	0.53	-0.85	0.82	-0.43	0.43	0.77	-0.48	0.43	-0.69	0.44	-0.66	0.53	0.47	0.92	0.68	0.01	0.03		0.43	-0.68	0.38	0.2	0.43
Property Plant And Equipment Gross	-0.15	0.68	-0.07	0.81	-0.35	0.0	-0.02	0.99	0.55	-0.36	0.7	-0.46	0.46	-0.48	0.63	0.29	0.13	0.46	0.1	0.21	0.43		-0.41	0.26	0.24	0.99
Total Current Assets	0.83	-0.67	-0.38	-0.58	0.87	-0.46	0.5	-0.46	-0.95	0.28	-0.74	0.99	-0.4	0.98	-0.75	-0.2	-0.53	-0.59	-0.23	-0.02	-0.68	-0.41		-0.32	-0.05	-0.46
Intangible Assets	0.25	0.56	0.26	0.21	-0.05	0.21	-0.52	0.32	0.43	0.55	0.64	-0.32	0.98	-0.21	0.42	-0.57	0.31	-0.09	0.16	-0.85	0.38	0.26	-0.32		-0.76	0.29
Common Stock	-0.44	0.04	0.1	0.39	-0.41	0.09	0.47	0.16	0.06	-0.95	-0.28	-0.08	-0.65	-0.18	-0.02	0.95	0.09	0.62	-0.12	0.96	0.2	0.24	-0.05	-0.76		0.18
Property Plant Equipment	-0.19	0.68	-0.13	0.77	-0.37	0.02	-0.1	1.0	0.58	-0.31	0.75	-0.51	0.49	-0.52	0.67	0.23	0.14	0.42	0.11	0.18	0.43	0.99	-0.46	0.29	0.18

Click cells to compare fundamentals

Mereo BioPharma Account Relationship Matchups

Mereo BioPharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	86.4M	62.9M	126.4M	88.1M	66.5M	70.1M
Short Long Term Debt Total	32.4M	17.9M	16.8M	12.8M	6.0M	5.7M
Other Current Liab	354K	4.6M	1.3M	10.0M	30K	28.5K
Total Current Liabilities	29.9M	8.6M	12.5M	24.7M	9.5M	14.3M
Total Stockholder Equity	40.3M	(15.0M)	88.0M	61.9M	50.5M	44.6M
Other Liab	1.6M	52.1M	9.7M	311K	357.7K	339.8K
Net Tangible Assets	(4.2M)	(46.6M)	63.4M	37.8M	43.4M	45.6M
Property Plant And Equipment Net	11.6M	1.6M	2.5M	1.8M	1.7M	2.4M
Net Debt	16.1M	(5.5M)	(77.5M)	(43.6M)	(51.5M)	(54.0M)
Retained Earnings	(146.1M)	(309.7M)	(297.0M)	(331.2M)	(419.6M)	(398.6M)
Accounts Payable	6.4M	3.3M	2.3M	3.1M	2.3M	2.8M
Cash	16.3M	23.5M	94.3M	56.3M	57.4M	55.8M
Non Current Assets Total	56.0M	33.2M	27.1M	25.9M	2.7M	2.6M
Non Currrent Assets Other	(56.0M)	(33.2M)	(27.1M)	(25.9M)	(23.4M)	(24.5M)
Long Term Debt	5.4M	16.1M	14.4M	4.4M	5.1M	4.8M
Cash And Short Term Investments	16.3M	23.5M	94.3M	56.3M	57.4M	41.0M
Net Receivables	12.0M	4.6M	1.8M	2.7M	3.7M	4.2M
Common Stock Total Equity	213.3K	213.7K	294K	1.0M	1.2M	1.2M
Common Stock Shares Outstanding	89.4M	339.0M	555.3M	603.2M	659.5M	692.4M
Short Term Investments	544K	547K	569K	51.1M	58.8M	61.7M
Liabilities And Stockholders Equity	86.4M	62.9M	126.4M	88.1M	66.5M	70.1M
Non Current Liabilities Total	16.3M	69.4M	25.9M	1.5M	6.5M	6.2M
Capital Lease Obligations	11.9M	1.8M	2.4M	1.7M	1.6M	2.4M
Inventory	(12.0M)	(4.6M)	(1.8M)	(2.7M)	1.2M	1.3M
Other Current Assets	14.1M	6.3M	5.0M	5.8M	1.4M	1.3M
Other Stockholder Equity	138.7M	160.5M	246.3M	253.2M	484.9M	509.1M
Total Liab	46.2M	77.9M	38.4M	26.2M	16.0M	15.2M
Property Plant And Equipment Gross	13.3M	1.6M	4.1M	3.4M	2.5M	3.1M
Short Long Term Debt	1.9M	6.8M	15.1M	11.1M	12.7M	6.4M
Total Current Assets	30.4M	29.7M	99.3M	62.1M	63.8M	64.2M
Accumulated Other Comprehensive Income	47.3M	133.2M	136.9M	137.9M	(17.5M)	(16.6M)
Non Current Liabilities Other	44K	62K	80K	182K	764K	802.2K
Short Term Debt	17.7M	636K	622K	11.6M	652K	619.4K
Intangible Assets	44.5M	31.6M	24.6M	24.1M	1.1M	1.0M
Common Stock	294K	1.0M	1.8M	1.9M	2.8M	2.9M
Property Plant Equipment	11.6M	1.6M	2.5M	1.8M	2.1M	2.5M
Current Deferred Revenue	(177.7K)	5.4M	8.4M	6.5M	7.4M	4.4M
Net Invested Capital	60.8M	1.2M	102.4M	73.0M	54.9M	49.1M

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Mereo Stock

0.6	DNA	Ginkgo Bioworks Holdings	Pair Corr
0.47	MNMD	Mind Medicine	Pair Corr
0.46	INAB	In8bio Inc	Pair Corr
0.46	LPCN	Lipocine	Pair Corr
0.37	INKT	Mink Therapeutics	Pair Corr

The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.

The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:

How To Invest In Mereo

Details

Is Mereo Stock a good investment?

Details

What is Mereo BioPharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.25)

Revenue Per Share

0.007

Return On Assets

(0.24)

Return On Equity

(0.48)

The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mereo Historical Balance Sheet

Mereo BioPharma Inventory

1.31 Million

About Mereo Balance Sheet Analysis

Mereo BioPharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Mereo BioPharma balance sheet Correlations

Mereo BioPharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mereo BioPharma balance sheet Accounts

Pair Trading with Mereo BioPharma

Moving against Mereo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accumulated Amortization	Total Assets
Short Long Term Debt Total	Other Current Liab
Total Current Liabilities	Total Stockholder Equity
Other Liab	Net Tangible Assets
Property Plant And Equipment Net	Total Permanent Equity
Warrants	Noncontrolling Interest In Consolidated Entity
Net Debt	Retained Earnings
Accounts Payable	Cash
Non Current Assets Total	Non Currrent Assets Other
Other Assets	Long Term Debt
Cash And Short Term Investments	Net Receivables
Good Will	Common Stock Total Equity
Retained Earnings Total Equity	Common Stock Shares Outstanding
Short Term Investments	Long Term Debt Total
Liabilities And Stockholders Equity	Non Current Liabilities Total
Capital Surpluse	Capital Lease Obligations
Negative Goodwill	Inventory
Other Current Assets	Other Stockholder Equity
Total Liab	Additional Paid In Capital
Deferred Long Term Liab	Preferred Stock Redeemable
Long Term Investments	Property Plant And Equipment Gross
Short Long Term Debt	Preferred Stock Total Equity
Total Current Assets	Accumulated Other Comprehensive Income
Treasury Stock	Non Current Liabilities Other
Accumulated Depreciation	Deferred Long Term Asset Charges
Short Term Debt	Intangible Assets
Common Stock	Temporary Equity Redeemable Noncontrolling Interests
Property Plant Equipment	Current Deferred Revenue
Net Invested Capital	Net Working Capital
Capital Stock

Property Plant Equipment	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Property Plant Equipment	+ 0.99	Property Plant And Equipment Gross
Intangible Assets	+ 0.98	Non Current Assets Total

Common Stock Total Equity	- 0.99	Retained Earnings
Cash	- 0.98	Net Debt
Common Stock	- 0.95	Retained Earnings
Total Current Assets	- 0.95	Net Debt
Cash And Short Term Investments	- 0.95	Net Debt
Other Stockholder Equity	- 0.86	Retained Earnings